Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatm...
Expands global intellectual property coverage in markets with high breast cancer incidence New patent will provide IP protecti...
D. Boral Capital analyst Jason Kolbert maintains Anixa Biosciences (NASDAQ:ANIX) with a Buy and maintains $10 price target.
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatm...
D. Boral Capital analyst Jason Kolbert maintains Anixa Biosciences (NASDAQ:ANIX) with a Buy and maintains $10 price target.
Phase 1 Data Highlights Potential of First-in-Class Vaccine to Transform Breast Cancer Treatment and PreventionComprehensive Re...
HC Wainwright & Co. analyst Yi Chen reiterates Anixa Biosciences (NASDAQ:ANIX) with a Buy and maintains $7 price target.
- SEC Filing
Anixa Biosciences (NASDAQ:ANIX) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0...
